Medical Pharmacology Chapter 36:  Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

Previous Page

Page Forward

Section Table of Contents

Site Table of Contents


  1. Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  2. Fauci AS Lane HC Chapter 226, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Kasper DL Fauci AS Hauser SL Longo DL Jameson JL Loscalzo J, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015 (on-line edition)

  3. Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012.

  4. Woster PM Chapter 43:  Antiviral Agents and Protease Inhibitors in Foye's Principles of Medicinal Chemistry 6e, Lemke, TL Williams DA, eds; Roche VG Zito SW, asst eds) Wolters Kluwer|Lippincott Williams & Wilkins 1214, 2008.

  5. HIV Overview:  The HIV Life Cycle, Education Materials, AIDSinfo, NIH

  6. Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version.

  7. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition.

  8. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014,

  9. Evering TH Markowitz M HIV-1 Integrase Inhibitors PRN Notebook 13 1-9, June 2008

  10. AIDSinfo:  Guidelines for the Use of Antriretroviral Agents in HIV-1-Infected Adults and Adolescents (2015)

  11. HIV Drug Resistance Data Base (Stanford University):  Integrase Inhibitor Resistance Notes (3/2014),

  12. Cahn P Pazniak AL Mingrone H Shuldyakov A Crites C Andrade-Villanueva JF Richmond G Buendia CB Fourie J Ramgopal M Hagins D Felizarta F Madruga J Reuter T Newman T Small CB Lombaard J Brinsztejn B Dorey D Underwood M Griffith S Min S on behalf of the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV:  week 48 results from the randomised, double-blind, non-inferiority SAILING study. The Lancet, published online July 3, 2013.

  13. Katz MH Zolopa AR HIV Infection & AIDS, Chapter 31 in Current Medical Diagnosis & Treatment 2015 (Papadakis MA McPhee SJ Rabow MW, eds), 54th edition, McGraw-Hill Education, 2015.

  14. Abram ME Hluhanich RM Boodman DD Andreatta KN Margot NA Ye L Niedziela-Majka A Barnes TL Novikov N Chen X Svarovakaia ES McColl DJ White KL Miller MD.  Impact of primary elvitegravir Resistance-mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrobial Agents and Chemotherapy 57(6): 2654-2663 June 2013. (;

  15. NCBI:  Gene-UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 [Homo sapiens (human)] Gene ID: 54658 (updated 30-Aug-2015)

  16. Ramanathan S Mathias AA German P Kearney BP Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.  Clin Pharmacokinet 50(4):  229-244, 2011.

  17. Sax PE DeJusus E Mills Zolopa A Cohen C Wohl D Gallant JE Liu HC Zhong L Yale K White K Kearney BP Szwarcberg J Quirk E Cheng AK, for the GS-US-236-0102 study team.  Co-formulated evitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection:  a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.  Lancet 379:  2439-2448, 2012.

  18. Zolopa A Sax PE DeJusus E Mills A Cohen C Wohl D Gallant JE Liu HC Plummer A White KL Cheng AK Rhee MS Szwarcberg J for the GS-US-236-0102 Study Team.  A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection:  analysis of week 96 results.  J Acquir Immune Defic Syndr 63:  96-100, 2013.

  19. Wood BR, Medical Director, NW AETC ECHO, Assistant Professor of Medicine, University of Washington. Stribild (aka The Quad Pill)



This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.